PharmaCyte Biotech (PMCB) Cash from Financing Activities (2010 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Cash from Financing Activities of -$169818.0 for Q2 2026, up 1.01% year-over-year from -$168127.3 in Q2 2025, and down 131.23% quarter-over-quarter from $543779.0 in Q1 2026.
PharmaCyte Biotech (PMCB) Cash from Financing Activities (2010 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Cash from Financing Activities for 17 consecutive years, with -$169818.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Financing Activities rose 1.01% year-over-year to -$169818.0; the TTM figure through Apr 2026 stood at $6.6 million (up 126.3% YoY), while the FY2026 annual figure was $6.6 million, up 126.3% from the prior year.
- Cash from Financing Activities eased to -$169818.0 in Q2 2026 per PMCB's latest filing, from $543779.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $6.3 million in Q3 2023 and bottomed at -$10.7 million in Q4 2024.
- Historically, Cash from Financing Activities has averaged -$2.7 million across 5 years, with a median of -$2.7 million in 2022.
- On a YoY basis, Cash from Financing Activities climbed as much as 400.44% in 2023 and fell as far as 8376.76% in 2023.
- PharmaCyte Biotech's Cash from Financing Activities stood at -$3.4 million in 2022, then soared by 122.12% to $748687.0 in 2023, then slumped by 1534.56% to -$10.7 million in 2024, then jumped by 157.8% to $6.2 million in 2025, then slumped by 102.74% to -$169818.0 in 2026.
- Business Quant data shows PMCB's Cash from Financing Activities at -$169818.0 in Q2 2026, $543779.0 in Q1 2026, and $6.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - | -169,818.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -169,818.00 |
| Apr 30, 2026 | -169,818.00 |
| Jan 31, 2026 | 543,779.00 |
| Jan 31, 2026 | 543,779.00 |
| Oct 31, 2025 | 6.21 Mn |
| Oct 31, 2025 | 6.21 Mn |
| Apr 30, 2025 | -171,543.00 |
| Apr 30, 2025 | -171,543.00 |
| Jan 31, 2025 | -3.95 Mn |
| Jan 31, 2025 | -3.95 Mn |
| Oct 31, 2024 | -10.74 Mn |
| Oct 31, 2024 | -10.74 Mn |
| Jul 31, 2024 | -10.17 Mn |
| Jul 31, 2024 | -10.17 Mn |
| Apr 30, 2024 | -10.70 Mn |
| Apr 30, 2024 | -10.70 Mn |
| Jan 31, 2024 | -7.04 Mn |
| Jan 31, 2024 | -7.04 Mn |
| Oct 31, 2023 | 748,687.00 |
| Oct 31, 2023 | 748,687.00 |